Immature granulocytes as a biomarker for diabetic retinopathy progression without anti-VEGF therapy: A cross sectional study

被引:0
作者
Bayram, Ergul [1 ]
Zor, Ramazan Kursad [2 ]
Ayan, Durmus [1 ,3 ]
机构
[1] Nigde Omer Halisdemir Univ, Res & Training Hosp, Med Biochem, Nigde, Turkiye
[2] Nigde Omer Halisdemir Univ, Fac Med, Ophthalmol, Nigde, Turkiye
[3] Nigde Omer Halisdemir Univ, Fac Med, Med Biochem, Nigde, Turkiye
关键词
Diabetic retinopathy; Immature granulocyte count; Immature granulocyte percentage; Inflammation; Delta neutrophil index; DELTA NEUTROPHIL INDEX; IMMUNE-INFLAMMATION INDEX; TO-LYMPHOCYTE RATIO; PROGNOSTIC MARKER; RESPONSE INDEX; COUNT; INFECTION;
D O I
10.1007/s13410-025-01484-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Diabetic retinopathy (DR) is one of the most common complications of diabetes and is the leading cause of low vision and blindness worldwide. Objective The present study aimed to evaluate delta neutrophil index (DNI), the immature granulocyte count (IG#), and percentage (IG%) in the diabetic group without retinopathy and in the diabetic group with DR. Methods A total of 175 participants were diagnosed with diabetes mellitus (DM (non-DR), 128 patients were diagnosed with nonproliferative diabetic retinopathy (NPDR) (n = 89), and one was diagnosed with diabetic proliferative retinopathy (PDR) (n = 39). Results The level of GR# and GR% in PDR was statistically significant than non-DR and NPDR (P = 0.03 and p = 0.02, respectively). The sensitivity and specificity of GR# and GR% for predicting progression from NPDR to PDR were determined to be 66.7% and 44.9%, respectively (area under curve [AUC] = 0.621, p = 0.029; 95% confidence interval [CI] = 0.512-0.730; and area under curve [AUC] = 0.623, p = 0.027, 95% confidence interval [CI] = 0.517-0.728). Additionally, IG# was not an independent risk factor for DR (p > 0.05). There were no significant differences in DNI among the NDR, NPDR, and PDR groups (p > 0.05). Conclusion IG# and IG% may be promising minimally invasive biomarkers for distinguishing NPDR from PDR but not DNI. We believe that they are markers that need to be confirmed in prospective studies for obtaining more reliable results in the detection of DR.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Levels of anti-insulin antibodies in diabetic retinopathy patients: an observational cross-sectional study
    Mohammed, Bismark N.
    Ofori, Emmanuel K.
    Adekena, Christian N.
    Amponsah, Seth K.
    Asare-Anane, Henry
    Amanquah, Seth D.
    Abdul-Rahman, Mubarak
    Amissah-Arthur, Kwesi N.
    FUTURE SCIENCE OA, 2024, 10 (01):
  • [42] Multi-Omics Integration With Machine Learning Identified Early Diabetic Retinopathy, Diabetic Macula Edema and Anti-VEGF Treatment Response
    Pang, Yuhui
    Luo, Chaokun
    Zhang, Qingruo
    Zhang, Xiongze
    Liao, Nanying
    Ji, Yuying
    Mi, Lan
    Gan, Yuhong
    Su, Yongyue
    Wen, Feng
    Chen, Hui
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2024, 13 (12):
  • [43] Effect of Periodontal Disease on Diabetic Retinopathy in Type 2 Diabetic Patients: A Cross-Sectional Pilot Study
    Yamamoto, Yuko
    Morozumi, Toshiya
    Hirata, Takahisa
    Takahashi, Toru
    Fuchida, Shinya
    Toyoda, Masami
    Nakajima, Shigeru
    Minabe, Masato
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 11
  • [44] AAV8 gene therapy encoding anti-VEGF Fab Treatment of wet age-related macular degeneration Treatment of diabetic retinopathy
    Desideri, Lorenzo Ferro
    Vaccaro, Sabrina
    Vagge, Aldo
    Nicolo, Massimo
    Scorcia, Vincenzo
    Traverso, Carlo Enrico
    Giannaccare, Giuseppe
    DRUGS OF THE FUTURE, 2022, 47 (10) : 737 - 741
  • [45] Appropriate timing schedule for intravitreal anti-VEGF injection as adjuvant therapy before pars-plana vitrectomy in proliferative diabetic retinopathy, a meta analysis
    Bagheri, Masood
    Salari, Nader
    Aghaei, Naser
    Yarmohammadi, Maryam
    EXPERT REVIEW OF OPHTHALMOLOGY, 2023, 18 (03) : 205 - 222
  • [46] Efficacy of anti-VEGF monotherapy versus anti-VEGF therapy with subthreshold micropulse laser (SML) in the management of diabetic macular oedema (DMO): a systematic review and meta-analysis
    Wijeweera, Chandana
    Ni, Jing
    Petocz, Peter
    Preda, Veronica
    Jabbour, James
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (09) : 2733 - 2749
  • [47] AST/ALT ratio is an independent risk factor for diabetic retinopathy: A cross-sectional study
    Luo, Jian
    Yu, Fang
    Zhou, Haifeng
    Wu, Xueyan
    Zhou, Quan
    Liu, Qin
    Gan, Shenglian
    MEDICINE, 2024, 103 (26) : e38583
  • [48] Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?
    Georgalas, Ilias
    Papaconstantinou, Dimitris
    Papadopoulos, Kostas
    Pagoulatos, Dionisis
    Karagiannis, Dimitris
    Koutsandrea, Chryssanthi
    CURRENT DRUG SAFETY, 2014, 9 (02) : 156 - 158
  • [49] Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review
    Vitiello, Livio
    Salerno, Giulio
    Coppola, Alessia
    De Pascale, Ilaria
    Abbinante, Giulia
    Gagliardi, Vincenzo
    Lixi, Filippo
    Pellegrino, Alfonso
    Giannaccare, Giuseppe
    LIFE-BASEL, 2024, 14 (06):
  • [50] Diabetic Retinopathy and Diabetic Macular Edema in a population of Antioquia. Cross-sectional study
    David Bravo, Juan
    Correa, Alexandra
    Bravo, Andres
    Bravo, Ricardo
    Alonso Villada, Oscar
    IATREIA, 2022, 35 (02) : 98 - 107